The SLC6A3 gene is involved in the dopamine pathway, which influences smoking behavior. This study was conducted to present updated results of a meta-analysis to evaluate the association between SLC6A3 polymorphism and smoking cessation. In total, eight studies were assessed, and 9-repeat alleles and no 9-repeat alleles were compared by smoking cessation outcomes. No significant association between SLC6A3 genotype and smoking cessation was observed for the main analysis (odds ratio = 1.128; 95% confidence interval = 0.981–1.298). In conclusion, the genetic variations in SLC6A3 are not associated with smoking cessation, which is not consistent with the results of the previous meta-analysis.
BeggCBMazumdarM (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics50: 1088–1101.
2.
BergCJCoxLSChoiWS. (2012) Assessment of depression among African American light smokers. Journal of Health Psychology17: 197–206.
3.
CochranWG (1954) The combination of estimates from different experiments. Biometrics10: 101–129.
4.
CookEHJrSteinMAKrasowskiMD. (1995) Association of attention-deficit disorder and the dopamine transporter gene. American Journal of Human Genetics56: 993–998.
5.
DavidSPMunafòMR (2008) Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics9: 1307–1321.
6.
DerSimonianRLairdN (1986) Meta-analysis in clinical trials. Control Clinical Trials17: 177–188.
7.
DickeKESkrlinSMMurphySE (2005) Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metabolism and Disposition33: 1760–1764.
8.
EggerMSmithGDSchneiderM. (1997) Bias in meta-analysis detected by a simple, graphical test. British Medical Journal315: 629–634.
9.
FukeSSuoSTakahashiN. (2001) The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. The Pharmacogenomics Journal1: 152–156.
10.
GelernterJKranzlerHRSatelSL. (1994) Genetic association between dopamine transporter protein alleles and cocaine-induced paranoia. Neuropsychopharmacology11: 195–200.
11.
HanDHJoeKHNaC. (2008) Effect of genetic polymorphisms on smoking cessation: A trial of bupropion in Korean male smokers. Psychiatric Genetics18: 11–16.
12.
HansenFHSkjørringeTYasmeenS. (2014) Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. Journal of Clinical Investigation124: 3107–3120.
13.
HeinzAGoldmanD (2000) Genotype effects on neurodegeneration and neuroadaptation in monoaminergic neurotransmitter systems. Neurochemistry International37: 425–432.
14.
JacobsenLKStaleyJKZoghbiSS. (2000) Prediction of dopamine transporter binding availability by genotype: A preliminary report. The American Journal of Psychiatry157: 1700–1703.
15.
JasiewiczAGrzywaczAJabłońskiM. (2014) The analysis of the polymorphic variations of the dopamine gen transporter (DAT1) and the serotonin transporter (5-HTTLPR) in patients with alcohol dependence syndrome with inclusion of the phenotypic feature of sweet liking preference. Psychiatria Polska48: 89–103.
16.
JormAFHendersonASJacombPA. (2000) Association of smoking and personality with a polymorphism of the dopamine transporter gene: Results from a community survey. American Journal of Medical Genetics96: 331–334.
17.
KalamidaDPoulasKAvramopoulouV. (2007) Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. FEBS Journal274: 3799–3845.
18.
LermanCShieldsPGAudrainJ. (1998) The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiology, Biomarkers and Prevention7: 253–255.
19.
LermanCShieldsPGWileytoEP. (2003) Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology22: 541–548.
20.
MantelNHaenszelW (1959) Statistical aspects of the analysis of data from retrospective sties of diseases. Journal of the National Cancer Institute22: 719–748.
21.
MoherDLiberatiATetzlaffJ. (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. PLoS Medicine6: e1000097.
22.
MwenifumboJCTyndaleRF (2007) Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics8: 1385–1402.
23.
NaughtonFMcEwenASuttonS (2015) Use and effectiveness of lapse prevention strategies among pregnant smokers. Journal of Health Psychology20: 1427–1433.
24.
O’GaraCStapletonJSutherlandG. (2007) Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenetics and Genomics17: 61–67.
25.
PolosaRBenowitzNL (2011) Treatment of nicotine addiction: Present therapeutic options and pipeline developments. Trends in Pharmacological Sciences32: 281–289.
26.
SabolSZNelsonMLFisherC. (1999) A genetic association for cigarette smoking behavior. Health Psychology18: 7–13.
27.
StapletonJASutherlandGO’GaraC (2007) Association between dopamine transporter genotypes and smoking cessation: A meta-analysis. Addiction Biology12: 221–226.
28.
StynMANukuiTRomkesM. (2009) The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics150: 254–261.
29.
TonTGRossingMABowenDJ. (2007) Genetic polymorphisms in dopamine-related genes and smoking cessation in women: A prospective cohort study. Behavioral and Brain Functions23: 3–22.
30.
VandenberghDJBennettCJGrantMD. (2002) Smoking status and the human dopamine transporter variable number of tandem repeats (VNTR) polymorphism: Failure to replicate and finding that never-smokers may be different. Nicotine & Tobacco Research4: 333–340.
31.
VandenberghDJPersicoAMHawkinsAL. (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics14: 1104–1106.
32.
Van DyckCHMalisonRTJacobsenLK. (2005) Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. Journal of Nuclear Medicine46: 745–751.
33.
WellsGSheaBO’ConenellD, et al. (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality for nonrandomized studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 14 March 2014).
34.
YamazakiHInoueKHashimotoM. (1999) Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Archives of Toxicology73: 65–70.
